ARCHIVES

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

NCAB Criticizes Coverage’ Of NCI Screening Statement

March 4, 1994

Conferees Agree On $815 Million For NCI In ‘77

July 30, 1976

Harold Varmus Nominated For NIH Director; Selection Wins Support of Biomedical Community

August 13, 1993

Newcomers Undercut Price of BRCA Test; Myriad Lawsuits Claim Patent Infringement

July 25, 2013

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

April 26, 2013

Funding Mechanisms: How They Are Used

August 12, 1983